Dianthus Therapeutics, Inc.

What they do

Dianthus develops monoclonal antibody and fusion protein candidates for autoimmune indications. Its lead candidate, claseprubart, is engineered to selectively inhibit only the active C1s complement protein with extended half-life, supporting subcutaneous self-administration. Claseprubart is in mid- to late-stage trials in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). The company is also developing DNTH212 for rheumatology indications and DNTH312, a next-generation bifunctional fusion protein combining claseprubart and TACI.

Revenue drivers

• Claseprubart (lead candidate) — No product revenue; the company has never generated product revenue. Claseprubart is the most advanced asset and is being studied in Phase 3 CAPTIVATE in CIDP, Phase 3 EMERGE in gMG, and Phase 2 MoMeNtum in MMN.
• DNTH212 — A clinical-stage bifunctional fusion protein targeting pDC BDCA2 and BAFF/APRIL, being developed for Sjogren's Disease (SjD), Systemic Lupus Erythematosus (SLE), and Dermatomyositis (DM). Phase 1 healthy volunteer data are anticipated by year-end 2026.
• DNTH312 — An internally developed first-in-class next-generation bifunctional fusion protein combining claseprubart and TACI, targeting aC1s and BAFF/APRIL; the company aims for it to be Phase 1 ready by year-end 2027.

Recent performance

Dianthus reported total annual revenue of $2.0 million in 2025, down from $6.2 million in 2024, with no product sales. Net loss widened to $162.3 million in 2025 from $85.0 million in 2024, and operating cash flow was negative $129.1 million. For Q2 2026, the company reported cash and equivalents of $110.5 million as of June 30, 2026, with total assets of $1.21 billion and total liabilities of $41.2 million. The company states approximately $1.2 billion of cash as of June 30, 2026 provides an expected runway into 2030. Recent quarterly revenue figures have been minimal, ranging from $193,000 to $1.2 million.

Strategy

The company is advancing claseprubart across three neuromuscular indications, with the Phase 3 EMERGE trial in gMG initiated in June 2026. In March 2026, it announced an early GO in the interim responder analysis of the Phase 3 CAPTIVATE trial in CIDP, and in June 2026 reported a 75% response rate from the first 40 participants completing Part A. Enrollment in the Phase 2 MoMeNtum trial in MMN was completed, exceeding the original target of 36 patients, with top-line results expected in December 2026. The company is also building a rheumatology franchise with DNTH212, anticipating Phase 1 healthy volunteer data by year-end 2026, and advancing DNTH312 toward Phase 1 readiness by year-end 2027.

Risks

• No approved products or product revenue — The company has no products approved for commercial sale, has not completed any late-stage clinical trials, and may never generate product revenue or become profitable.
• Substantial additional capital required — Dianthus will require substantial additional capital to finance operations, and failure to raise capital on acceptable terms could force it to delay, reduce, or eliminate clinical trials or development programs.
• Significant and growing losses — The company has incurred significant losses since inception, with a net loss of $162.3 million in 2025, and expects to incur significant losses for the foreseeable future.
• Competition in target indications — Dianthus faces competition from entities that have developed or may develop programs for the diseases it plans to address with claseprubart, DNTH212, and other candidates.

Outlook

Management expects top-line results from the Phase 3 EMERGE trial in gMG in the second half of 2028. CAPTIVATE Part B top-line guidance is expected by year-end 2026, and Phase 2 MoMeNtum top-line results in MMN are expected in December 2026. Phase 1 healthy volunteer data for DNTH212 are anticipated by year-end 2026, and DNTH312 is targeted to be Phase 1 ready by year-end 2027. The company states its approximately $1.2 billion of cash as of June 30, 2026 provides an expected runway into 2030.